I至III期结直肠癌的复发率及复发时间:一项丹麦全国性队列研究
该丹麦全国队列研究纳入2004至2019年行根治性原发手术的34 166例UICC I至III期结直肠癌患者,随访5年,采用累积发生率函数评估分期特异性复发率。结果显示结肠癌和直肠癌各期5年复发累积发生率在三个日历年段均下降,III期较I期复发时间更短(时间比0.30;95%CI 0.28-0.32),筛查发现的癌症复发风险更低(sHR 0.81;95%CI 0.73-0.91)。
要点
- 结肠癌5年复发累积发生率从第一时段至第三时段:I期16.3%降至6.8%,II期21.9%降至11.6%,III期35.3%降至24.6%。
- 直肠癌5年复发累积发生率从第一时段至第三时段:I期19.9%降至9.5%,II期25.8%降至18.4%,III期38.7%降至28.8%。
- III期较I期术后至复发时间更短(时间比0.30;95%CI 0.28-0.32),筛查发现者较非筛查发现者复发风险更低(sHR 0.81;95%CI 0.73-0.91)。
核心结论
- 在该结直肠癌队列中,I至III期患者的复发风险在研究期间下降。
- 通过筛查发现的癌症与更低的复发风险相关。
- 复发时间因UICC分期而异。
- 由于部分患者群体复发风险很低,作者认为未来研究有必要探索风险分层的监测方案。
研究设计与样本
- 丹麦全国性队列研究,使用丹麦结直肠癌组数据库识别2004年1月1日至2019年12月31日行原发手术的UICC I至III期结直肠癌患者。
- 共纳入34 166例患者,中位年龄70岁(IQR 62-77),男性18 552例(54.3%)。
- 随访至复发、死亡、第二癌症诊断、移居、术后5年或2023年1月1日,以先发生者为准。
- 复发状态通过丹麦癌症登记处、丹麦国家患者登记处和丹麦病理登记处的个体级链接数据及经验证的算法确定。
- 数据分析时间为2023年1月1日至8月8日。
主要发现
- 34 166例患者中,7027例在术后5年内发生复发。
- 结肠癌5年复发累积发生率从2004-2008至2014-2019时段:I期16.3%降至6.8%,II期21.9%降至11.6%,III期35.3%降至24.6%。
- 直肠癌5年复发累积发生率从2004-2008至2014-2019时段:I期19.9%降至9.5%,II期25.8%降至18.4%,III期38.7%降至28.8%。
- III期较I期术后至复发时间更短(时间比0.30;95%CI 0.28-0.32)。
- 筛查发现的癌症较非筛查发现的癌症,分期校正后复发风险更低(sHR 0.81;95%CI 0.73-0.91)。
关键数值与推荐
- 结肠癌5年复发累积发生率:I期16.3%降至6.8%,II期21.9%降至11.6%,III期35.3%降至24.6%(2004-2008至2014-2019时段)。
- 直肠癌5年复发累积发生率:I期19.9%降至9.5%,II期25.8%降至18.4%,III期38.7%降至28.8%(2004-2008至2014-2019时段)。
- III期较I期术后至复发时间比0.30(95%CI 0.28-0.32)。
- 筛查发现较非筛查发现癌症的分期校正复发风险sHR 0.81(95%CI 0.73-0.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Management of colorectal cancer (CRC) has been updated continuously over the past 2 decades. While the combination of these initiatives has had implications for improved survival, the implications for rates of recurrence remain unexplored. OBJECTIVE: To ascertain the rates of recurrence and describe time to recurrence within 5 years of surgery with curative intent for stages I to III CRC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the Danish Colorectal Cancer Group Database to identify patients with Union for International Cancer Control (UICC) stages I to III CRC who underwent primary surgery between January 1, 2004, and December 31, 2019. They were followed up until recurrence (event), death (competing event), diagnosis of a second cancer (competing event), emigration (censoring event), 5 years postoperatively (censoring event), or January 1, 2023 (censoring event), whichever came first. Recurrence status was ascertained through individual-level linked data from the Danish Cancer Registry, Danish National Patient Registry, and Danish Pathology Registry using a validated algorithm. Data were analyzed from January 1 to August 8, 2023. EXPOSURE: Primary surgery performed during 3 calendar periods (2004-2008, 2009-2013, and 2014-2019) stratified by tumor site (colon or rectum) and UICC stage (I, II, and III). MAIN OUTCOMES AND MEASURES: Stage-specific 5-year recurrence reported as the cumulative incidence function (CIF) of recurrence, the association between calendar period of primary surgery and recurrence risk reported as subdistribution hazard ratios (sHRs), and the time from surgery to recurrence. RESULTS: Of the 34 166 patients with UICC stages I to III CRC (median [IQR] age, 70 [62-77] years); 18 552 males [54.3%]) included in the study, 7027 developed recurrence within 5 years after the primary surgery. For colon cancer, the 5-year CIF of recurrence decreased over the 3 calendar periods from 16.3% to 6.8% for UICC stage I, from 21.9% to 11.6% for UICC stage II, and from 35.3% to 24.6% for UICC stage III colon cancer. For rectal cancer, the 5-year CIF decreased over the 3 periods from 19.9% to 9.5% for stage I, from 25.8% to 18.4% for stage II, and from 38.7% to 28.8% for stage III disease. Patients with stage III disease had a shorter time from surgery to recurrence compared with those with stage I disease (time ratio stage III vs stage I = 0.30; 95% CI, 0.28-0.32). Cancers detected through screening were associated with lower stage-adjusted risks of recurrence (sHR, 0.81; 95% CI, 0.73-0.91) compared with cancers not detected through screening. CONCLUSIONS AND RELEVANCE: In this cohort of patients with CRC, the risk of recurrence decreased in patients with stages I to III disease during the study period. Cancer detection by screening was associated with an even lower risk of recurrence. Time to recurrence differed according to UICC stage. Because the risk of recurrence was so low in selected patient groups, future research is warranted to explore risk-stratified surveillance protocols in patients with CRC.
引用
- Nors J, Iversen LH, Erichsen R, et al. Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncol. 2024. PMID: 37971197. doi:10.1001/jamaoncol.2023.5098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。